Institute for Wealth Management LLC. reduced its stake in shares of Sanofi SA (NYSE:SNY) by 6.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 18,269 shares of the company’s stock after selling 1,359 shares during the quarter. Institute for Wealth Management LLC.’s holdings in Sanofi were worth $933,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CFM Wealth Partners LLC bought a new position in shares of Sanofi during the first quarter worth about $25,000. AlphaCore Capital LLC bought a new position in shares of Sanofi during the first quarter worth about $29,000. Citizens Financial Group Inc RI bought a new position in shares of Sanofi during the first quarter worth about $44,000. Capital Square LLC bought a new position in shares of Sanofi during the first quarter worth about $51,000. Finally, Allworth Financial LP raised its position in shares of Sanofi by 128.5% during the second quarter. Allworth Financial LP now owns 1,092 shares of the company’s stock worth $56,000 after acquiring an additional 614 shares during the last quarter. 7.04% of the stock is currently owned by institutional investors.
Sanofi stock traded down $0.05 during mid-day trading on Friday, reaching $52.45. The stock had a trading volume of 2,802,341 shares, compared to its average volume of 2,018,114. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. Sanofi SA has a fifty-two week low of $37.62 and a fifty-two week high of $55.00. The stock’s 50-day simple moving average is $51.68 and its 200-day simple moving average is $48.67. The firm has a market capitalization of $131.34 billion, a PE ratio of 16.76, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67.
A number of brokerages have recently issued reports on SNY. Barclays restated an “equal weight” rating on shares of Sanofi in a research report on Tuesday, April 28th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Sanofi in a research note on Friday. Morgan Stanley reaffirmed an “overweight” rating on shares of Sanofi in a research note on Tuesday, June 9th. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $50.00 target price for the company in a research note on Monday, May 18th. Finally, UBS Group reaffirmed a “buy” rating on shares of Sanofi in a research note on Tuesday, May 26th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $54.00.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.